Nigel S. Key
Impact in
- Internal Medicine top 0.05%
- Venous Thromboembolism Diagnosis and Management
- Hematology top 0.05%
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Iron Metabolism and Disorders
Papers in
- Hematology 258
- Hemophilia Treatment and Research 119
- Blood Coagulation and Thrombosis Mechanisms 107
- Platelet Disorders and Treatments 78
- Iron Metabolism and Disorders 38
- Genetics 128
- Hemoglobinopathies and Related Disorders 78
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 32
- Myeloproliferative Neoplasms: Diagnosis and Treatment 32
- Co-authors
- Nigel Mackman (31 shared papers)Alok Srivastava (4 shared papers)Robert P. Hebbel (9 shared papers)Arne Slungaard (13 shared papers)Kenneth I. Ataga (22 shared papers)Rachel E. Tilley (1 shared paper)Alok A. Khorana (6 shared papers)Howard A. Liebman (4 shared papers)
- Journals
- Blood (64 papers)Journal of Thrombosis and Haemostasis (32 papers)Haemophilia (31 papers)Thrombosis Research (22 papers)Blood Advances (17 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Nigel S. Key
389 papers receiving 22.6k citations
Nigel S. Key's Hit Papers
Peers
Comparison fields: 5 of 168
- Internal Medicine 5.3k
- Hematology 10.2k
- Genetics 4.1k
- Emergency Medical Services 927
- Critical Care and Intensive Care Medicine 622
Countries citing papers authored by Nigel S. Key
This map shows the geographic impact of Nigel S. Key's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel S. Key with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel S. Key more than expected).
Fields of papers citing papers by Nigel S. Key
This network shows the impact of papers produced by Nigel S. Key. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel S. Key. The network helps show where Nigel S. Key may publish in the future.
Co-authors
The 25 scholars most cited alongside Nigel S. Key, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 408 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Guidelines for the management of hemophilia Hit paper breakdown → | 2012 | 1534 |
| 2 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Hit paper breakdown → | 2019 | 1080 |
| 3 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014 Hit paper breakdown → | 2015 | 1057 |
| 4 | Definitions in hemophilia: communication from the SSC of the ISTH Hit paper breakdown → | 2014 | 601 |
| 5 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2013 | 596 |
| 6 | Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis Hit paper breakdown → | 2007 | 570 |
| 7 | D-dimer antigen: current concepts and future prospects Hit paper breakdown → | 2008 | 494 |
| 8 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer Hit paper breakdown → | 2019 | 485 |
| 9 | 2003 | 467 | |
| 10 | 2004 | 344 | |
| 11 | Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study Hit paper breakdown → | 2019 | 320 |
| 12 | 2010 | 318 | |
| 13 | 2013 | 312 | |
| 14 | 1998 | 303 | |
| 15 | 2009 | 272 | |
| 16 | 2004 | 262 | |
| 17 | Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B Hit paper breakdown → | 2023 | 260 |
| 18 | 2012 | 250 | |
| 19 | 1997 | 246 | |
| 20 | 1998 | 210 |
About Nigel S. Key
Nigel S. Key is a scholar working on Hematology, Genetics, Internal Medicine, Immunology and Pulmonary and Respiratory Medicine, having authored 408 papers that have together received 23.5k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (119 papers), Blood Coagulation and Thrombosis Mechanisms (107 papers), Platelet Disorders and Treatments (78 papers), Hemoglobinopathies and Related Disorders (78 papers), Venous Thromboembolism Diagnosis and Management (70 papers), Iron Metabolism and Disorders (38 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (32 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers). The work is most often cited by research in Internal Medicine (5.3k citations), Hematology (10.2k citations), Genetics (4.1k citations), Emergency Medical Services (927 citations) and Critical Care and Intensive Care Medicine (622 citations). Nigel S. Key has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Nigel Mackman, Alok Srivastava, Robert P. Hebbel, Arne Slungaard, Kenneth I. Ataga, Rachel E. Tilley, Alok A. Khorana, Howard A. Liebman, Raj S. Kasthuri and Soheir S. Adam. Their work appears in journals such as Blood, Journal of Thrombosis and Haemostasis, Haemophilia, Thrombosis Research and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.